Nucleotide excision repair is a DNA repair pathway that is highly conserved in nature, with analogous repair systems described in Escherichia coli, yeast, and mammalian cells. The rate-limiting step, DNA damage recognition and excision, is effected by the protein products of the genes ERCC1 and XPAC. We therefore assessed mRNA levels of ERCC1 and XPAC in malignant ovarian cancer tissues from 28 patients that were harvested before the administration of platinum-based chemotherapy. Cancer tissues from patients whose tumors were clinically resistant to therapy (n = 13) showed greater levels of total ERCC1 mRNA (P = 0.059), full length transcript of ERCC1 mRNA (P = 0.026), and XPAC mRNA (P = 0.011), as compared with tumor tissues from those individuals clinically sensitive to therapy (n = 15). In 19 of these tissues, the percentage of alternative splicing of ERCC1 mRNA was assessed. ERCC1 splicing was highly variable, with no difference observed between responders and nonresponders. The alternatively spliced species constituted 2-58% of the total ERCC1 mRNA in responders (median = 18%) and 4-71% in nonresponders (median = 13%). These data suggest greater activity of the DNA excision repair genes ERCC1 and XPAC in ovarian cancer tissues of patients clinically resistant to platinum compounds. These data also indicate highly variable splicing of ERCC1 mRNA in ovarian cancer tissues in vivo, whether or not such tissues are sensitive to platinum-based therapy. (J. Clin. Invest. 1994. 94:703-708.)
Introduction
Excision repair of bulky DNA adducts, such as those formed by cisplatin, appears to be mediated by an aggregate of genes, with ERCC and XP proteins being involved in DNA damage recognition and excision (1-3). The human DNA repair genes ERCC ' (the human excision repair gene cross-complementing Chinese hamster ovary [CHO] mutant cell lines of complementation group 1) and XPAC (the human excision repair gene that corrects the defect in xeroderma pigmentosum group A cells) have been cloned (4, 5) . Several studies using mutant human and hamster cell lines that are defective in either of these genes, and their transfected derivatives, and studies in human tumor tissues indicate that the products encoded by these genes are involved in the excision repair of platinum-DNA adducts (6) (7) (8) (9) .
We have been interested in ascertaining the relative levels of expression of excision repair genes in malignant cells from cancer patients receiving platinum-based therapy (6) . Currently accepted models of excision repair suggest that the damage recognition/excision step is rate-limiting to the excision repair process (3) . Studies on the homology of human excision repair genes with bacterial and yeast excision repair genes suggest that ERCC1 and XPAC may be the genes primarily involved in the recognition and excision of bulky DNA adducts (5, (10) (11) (12) . This occurs with the help of putative helicases encoded by ERCC2, ERCC3, and ERCC6 (2, 13) .
The present study examines relative mRNA levels of expression of ERCC1 and XPAC in ovarian cancer tissues. We also assess the levels of an alternatively spliced species of ERCC1 mRNA which does not contain exon VIII and is presumed to be nonfunctional. These studies have been done in tumor tissues taken from a cohort of 28 patients with ovarian cancer, before the initiation of platinum-based therapy. We believe that assessing patterns of mRNA expression of ERCC and XP genes may assist in understanding the molecular control of cellular resistance to DNA-damaging agents.
Methods
Tissues studied. Fresh tumor tissues were obtained from 28 patients with ovarian cancer. These tissues were obtained before treatment with cisplatin-or carboplatin-based chemotherapy. Patients from whom tissues were obtained participated in either of three approved experimental treatment protocols for advanced stage ovarian cancer that have been reported previously by the Medicine Branch of the National Cancer Institute (unpublished observations2, 14-16). Disease was followed by physical exam and by radiographic means, including abdominopelvic CT scan and/or ultrasound examination.
Complete response was defined as complete eradication of all evaluable disease, confirmed by peritoneoscopy. Partial response was defined as a > 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions lasting at least 1 mo. Progressive disease was a > 25% increase in the sum of the products of the perpendicular diameters of all measurable lesions or the appearance of new 2. Reed In vitro studies were performed using the ovarian cancer cell line A2780/CP70, which has been described previously by our laboratory (17) . PCR analyses. A reverse transcription/polymerase chain reaction (RT/PCR)-based assay system (6) was used to determine the level of expression of ERCC1, XPAC, and f3-actin. Tissues were stored at -800C and extracted for total RNA by hot phenolchloroform extraction (18) . cDNA was obtained from 10 1Lg of total RNA by reverse transcription using oligo-dT primers (Reverse Transcription System; Promega Corp., Madison, WI). cDNAs were washed and concentrated by ultrafiltration (Amicon, Beverly, MA) and resuspended to 100 pl in low TE buffer (10 mM Tris, pH 8.0, and 0.1 mM EDTA).
For ERCC1, primers and RT/PCR conditions were selected to affect amplification of a 481-bp segment, from 245 to 725 of the ERCC1 cDNA nucleotide sequence (19) and including exons III to VI of the ERCC1 gene (20) . For XPAC, primer and PCR conditions were optimized for amplification of a 531-bp segment from base 164 to base 694 (5) which spans a region that extends from within exon I to exon V (21) . Primers chosen for /-actin spanned a 731-bp segment of the coding region of the ,B-actin gene and extended from base 269 of exon II to base 1535 in exon IV (22 The median level of ERCC1 expression for the cohort of 28 patients was 0.18; and for XPAC the median level of expression was not detectable (< 0.01). When responders and nonresponders are assessed as a function of the median expression levels of these two genes, higher levels of expression were consistently seen in the nonresponder group. In nonresponders, 9 out of 13 showed ERCC1 levels higher than the median, and 8 out of 13 showed XPAC levels higher than the median. In responding patients, 5 out of 15 showed ERCC1 levels higher than the median, and 2 out of 15 showed XPAC levels higher than the median. Concurrent expression levels for both genes, which were higher than the median, were seen in 8 out of 13 tumors that were clinically resistant to platinum-based therapy and in 2 out of 15 tumors that were clinically sensitive. ease response groups for XPAC is statistically significant (P = 0.011), but for ERCC1 the relationship borders on significance (P = 0.059). Fig. 2 shows the graphic relationship between ERCC1 and XPAC for responding patients (A) and for nonresponders (B). For tumors sensitive to platinum-based therapy, XPAC expression is consistently extremely low regardless of the ERCC1 level (Fig. 2 A) . For tumors resistant to platinum-based therapy, there is a suggestion of coordinated expression of these two genes in those tissues (Fig. 2 B) . In platinum-resistant tumors, the shift of the curve to the right suggests that ERCC1 expression may be upregulated first, followed by upregulation of XPAC. Fig. 3 shows autoradiographs of the 19 samples assessed for the full length transcript of ERCC1, as well as the alternatively spliced species. In both responders and nonresponders, expression levels of both species were highly variable. Table  II shows a summary of the numerical values generated from cant (P = 0.026), whereas for the alternatively spliced species the difference only bordered on significance (P = 0.058). Table  II also shows a summary of the percentage of total ERCC1 which was nonfunctional (lacking exon VIII) in responding patients and in nonresponders. In responding patients, the per- 
Discussion
DNA repair is one of the three major molecular mechanisms through which cells become resistant to platinum compounds (25) . Studies in human ovarian cancer cells (17) , in human T lymphocytes (26) , and in murine L1210 leukemia cells (27, 28) all suggest that at low levels of platinum resistance (up to 10-15-fold over baseline) DNA repair is the most important mechanism of resistance.
The DNA repair gene XPAC has generally been studied with respect to UV repair deficiency states such as xeroderma pigmentosum (29) . This is the first report relating XPAC gene expression to the clinical treatment of a human malignant disease. ERCC1 has been studied in human ovarian cancer cells (6) (3) . This report suggests that in human ovarian cancer these two genes are directly related to clinical resistance to the DNA-damaging platinum compounds and supports the concept that these two genes work together in this process.
The XPAC gene product exhibits homology to the bacterial and yeast proteins uvrA and RAD14, respectively (5, 10). The section of XPAC mRNA that is amplified by PCR in our study, ranging from exon I to possibly exon V (21) , includes segments of the XPAC protein that are essential for DNA repair function (31) . These segments include a glutamic acid cluster in exon II that may bind histones and the DNA-binding zinc finger motif in exon HI (31) . The XPAC gene product is thus involved in the recognition of bulky DNA adducts and is essential for excision repair of bulky adducts (3, 8, 10) . The impaired ability of XPA-derived fibroblast cell lines to effect the repair of platinum-DNA adducts has been well documented (7, 32, 33) . In our study, significantly higher levels of XPAC mRNA were detected in the tumor tissues of patients resistant to platinumbased therapy, compared with tissues from patients responding to therapy. This is the first report suggesting the clinical importance of high levels of XPAC gene expression in determining the ability of malignant tissue to process platinum-DNA adducts.
The ERCC1 gene exhibits homology to the yeast RADIO gene (19), which forms an endonucleolytic complex with RADI, and is involved in the excision of bulky DNA adducts (11, 12) . When transfected into DNA-repair deficient CHO cells, ERCC1 confers cellular resistance to cisplatin along with the ability to repair platinum-DNA adducts (9) . Our present study indicates that concurrent high levels of expression of both ERCC1 and XPAC may translate into augmented tumor cell resistance to platinum-based therapy in ovarian cancer tissue. Concordance of ERCC1 and XPAC mRNA levels, as indicated by a high correlation coefficient, occurs in the tissues from patients resistant to platinum-based therapy. Thus, the concurrent augmentation in the expression of the XPAC and ERCC1 genes (which recognize and cleave bulky adducts) may result in the increased removal of DNA damage affected by platinum therapy. It is interesting to note that, in ovarian tumor tissue, upregulation of ERCC 1 appears to occur before an upregulation of XPAC gene expression (see Fig. 2 B) . A similar relationship between ERCC1 and other ERCC genes was observed in nonmalignant bone marrow from cancer patients and also in human ERCCl-transfected CHO cells (34) . In that study, the regulation of ERCC1 expression appeared to dictate the regulation of ERCC2 and ERCC6.
The presence of an altematively spliced species of ERCC1 mRNA lacking a 72-bp exon was first reported in a study of poly(A)+ RNA from HeLa and K562 cell lines and of human ERCC1 cDNA clones (19). In that study, transfection experiments indicated that only the cDNA from the full human ERCC1 transcript (which includes exon VIII) could complement the excision repair defect for UV and mitomycin C. In our study, significantly higher levels of the full ERCC1 mRNA transcript are associated with a lack of response to platinumbased therapy. In our analysis, patients resistant to platinumbased therapy also exhibit higher levels of the ERCC1 transcript devoid of exon VIII, but the difference is not statistically significant.
For total ERCC1, the difference between responders and nonresponders had a P value of 0.059, and for nonfunctional ERCC1 the P value was 0.058. One report has suggested that the smaller "nonfunctional" transcript for ERCC1 may indeed have a "helper" function for the repair of UV-and mitomycin C-induced DNA damage in some settings (35) . Since the P value for the full "functional" transcript for ERCC1 is 0.026, we believe that our clinical observations are consistent with the laboratory model regarding the functions of the full transcript and of the transcript lacking exon VIII.
The rate-limiting step in DNA excision repair is the damage recognition/excision step, which is mediated by genes of the ERCC and XP groups (3). Here, we have shown that mRNA levels of two of the key genes in this process, ERCC1 and XPAC, are directly related to clinical resistance to platinum compounds in human ovarian cancer. This suggests that the concurrent expression of both enzymes may increase the removal of the DNA damage effected by platinum therapy. Unraveling the molecular processes involved in clinical resistance to this type of therapy is the first step in the development of novel ways to selectively eradicate human malignant disease.
